Letter: immunotherapy in IBD patients in a SARS‐CoV‐2 endemic area
Open Access
- 14 August 2020
- journal article
- letter
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (5) , 898-899
Abstract
LINKED CONTENTThis article is linked to Taxonera et al papers. To view these articles, visit https://doi.org/10.1111/apt.15804 and https://doi.org/10.1111/apt.15955Keywords
This publication has 5 references indexed in Scilit:
- COVID-19 deaths: what we need in the next phaseCancer Nursing Practice, 2020
- 2019 novel coronavirus disease (COVID‐19) in patients with inflammatory bowel diseasesAlimentary Pharmacology & Therapeutics, 2020
- Coronavirus as silent killer: recent advancement to pathogenesis, therapeutic strategy and future perspectivesVirusDisease, 2020
- Escaping Pandora’s Box — Another Novel CoronavirusNew England Journal of Medicine, 2020
- A new coronavirus associated with human respiratory disease in ChinaNature, 2020